BioNTech price target raised to $113 from $107 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on BioNTech to $113 from $107 and keeps a Buy rating on the shares post the Q1 report. Despite the rapid decline in COVID-19 vaccine-related revenues, BioNTech remains an “intriguing opportunity based on its substantial war chest, burgeoning pipeline and plethora of approaching data releases,” the analyst tells investors in a research note.